Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation

Autor: Joanna W. Etra, Joseph Lopez, W. P. Andrew Lee, Felix Nägele, Georg J. Furtmüller, Dalibor Vasilic, Howard D. Wang, Amy Quan, Ali Ahmadi, Robert A. Montgomery, Samuel A.J. Fidder, Giorgio Raimondi, Zhaoli Sun, Gerald Brandacher, Burcu Akpinarli, Devin Miller, Joshua Budihardjo, Denver M. Lough
Přispěvatelé: Plastic and Reconstructive Surgery and Hand Surgery
Rok vydání: 2018
Předmět:
Graft Rejection
Male
Time Factors
medicine.medical_treatment
Hematopoietic stem cell transplantation
030230 surgery
Vascularized Composite Allotransplantation
Tacrolimus
03 medical and health sciences
0302 clinical medicine
Isoantibodies
medicine
Complement C4b
Animals
health care economics and organizations
Sensitization
Desensitization (medicine)
Transplantation
business.industry
Graft Survival
Hematopoietic Stem Cell Transplantation
Skin Transplantation
Myeloablative Agonists
humanities
Peptide Fragments
Hindlimb
Transplantation
Isogeneic

medicine.anatomical_structure
Desensitization
Immunologic

Rats
Inbred Lew

Antibody mediated rejection
Models
Animal

Cancer research
030211 gastroenterology & hepatology
Graft survival
Composite Tissue Allografts
business
Immunosuppressive Agents
Vidarabine
Zdroj: Transplantation, 102(4), 593-600. Lippincott Williams & Wilkins
ISSN: 0041-1337
Popis: Candidates for vascularized composite allotransplantation (VCA) are frequently sensitized, putting them at risk for antibody-mediated rejection. Current desensitization strategies are imperfect and require a living-donor setting. Here we investigated the impact of sensitization on and the efficacy of a desensitization protocol utilizing syngeneic hematopoietic stem cell transplantation (HSCT) to prevent antibody-mediated rejection in VCA.Skin transplants from Dark Agouti to Lewis rats were performed for sensitization. Orthotopic hind limb transplants from Dark Agouti donors were performed to sensitized and nonsensitized recipients, and the animals were treated with either daily tacrolimus or no immunosuppression. A desensitization protocol consisting of total body irradiation, fludarabine, and syngeneic HSCT was applied to sensitized animals. Graft rejection was monitored by clinical assessment and histological analysis. Serum levels of donor-specific antibodies (DSA IgG) were measured using flow cytometry.Sensitized recipients exhibited accelerated rejection by 5.5 ± 1.2 days without immunosuppression and 10.2 ± 3.6 days with daily tacrolimus compared with 8.7 ± 1.2 days and longer than 30 days in nonsensitized recipients, respectively. Serum levels of DSA IgG were markedly elevated (37.3 ± 3.34-fold from baseline) in sensitized recipients after VCA and correlated with histologic evidence of rejection and C4d deposition. Desensitization significantly reduced DSA compared with sensitized controls (2.6 ± 0.5-fold vs 6.0 ± 1.2-fold, P0.01) and along with daily tacrolimus led to improved VCA survival longer than 30 days without evidence of C4d deposition (n = 6).In summary, sensitization leads to accelerated rejection of VCA, and syngeneic HSCT combined with conventional immunosuppression effectively reduces DSA and improves allograft survival in sensitized rats.
Databáze: OpenAIRE